Program
autogene cevumeran
Also written as “Autogene cevumeran”, “Autogene Cevumeran” and “RO7198457 intravenous (IV)”.
Its studies are mostly in Melanoma · Colorectal Neoplasms · Adenocarcinoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 42 open or running | phase 2since Jan 7, 2019 | Sep 19, 2017 | Nov 10, 2027phase 2 · NCT06534983 |
| BioNTech | 11 open or running | phase 2since Jul 20, 2020 | Jul 20, 2020 | Nov 2026phase 2 · NCT04486378 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6180 autogene cevumeran (BioNTech)
, phase 2, as of Oct 22, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 19, 2017First study: phase 1 study in MelanomaNew to Hoffmann-La RocheHoffmann-La Roche · NCT03289962 · 273 enrolled · United States, Belgium, Canada and more
- Jan 7, 2019Phase 2 study in Advanced MelanomaHoffmann-La Roche · NCT03815058 · 131 enrolled · United States, Australia, Belgium and more
- Jul 20, 2020BioNTech's first study: phase 2 study in Colorectal NeoplasmsNew to BioNTechBioNTech · NCT04486378 · 327 enrolled · United States, Belgium, Canada and more
- Jul 21, 2023Phase 2 study in AdenocarcinomaHoffmann-La Roche · NCT05968326 · 260 enrolled · United States, Belgium, Canada and more
- Jul 30, 2024Phase 2 study in Muscle-invasive Urothelial CarcinomaHoffmann-La Roche · NCT06534983 · 62 enrolled · United States, Argentina, Australia and more
Ahead
- Nov 2026Primary completion: phase 2 study in Colorectal NeoplasmsBioNTech · NCT04486378
- Nov 10, 2027Primary completion: phase 2 study in Muscle-invasive Urothelial CarcinomaHoffmann-La Roche · NCT06534983
- Jan 1, 2031Primary completion: phase 2 study in AdenocarcinomaHoffmann-La Roche · NCT05968326
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“An mRNA-based individualized, therapeutic cancer vaccine targeting an unspecified amount of tumor-associated antigens (TAAs) that are specifically expressed in the patient's cancer, with potential immunostimulatory and antineoplastic activities. Upon administration, autogene cevumeran is taken up…”NCIt, read by Claude
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06534983Muscle-invasive Urothelial Carcinoma · United States, Argentina, Australia and more | 2 | Active, not recruiting | Hoffmann-La Roche | Nov 10, 2027 | 62 |
| NCT05968326Adenocarcinoma · United States, Belgium, Canada and more | 2 | Active, not recruiting | Hoffmann-La Roche | Jan 1, 2031 | 260 |
| NCT04486378Colorectal Neoplasms · United States, Belgium, Canada and more | 2 | Active, not recruiting | BioNTech | Nov 2026 | 327 |
| NCT03815058Advanced Melanoma · United States, Australia, Belgium and more | 2 | Completed | Hoffmann-La Roche | Jan 21, 2025 | 131 |
| NCT03289962Melanoma · United States, Belgium, Canada and more | 1 | Completed | Hoffmann-La Roche | Jul 1, 2025 | 273 |
How it is read
Names in the registry
- “Autogene cevumeran”, 3 entries
- “Autogene Cevumeran”, 1 entry
- “RO7198457 intravenous (IV)”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 2 studies
- Colorectal Neoplasms, 1 study
- Adenocarcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.